Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 2b symbols : AGNPF save search
Algernon Pharmaceuticals Announces Plans for a 180 Patient Phase 2b Chronic Cough Study of Ifenprodil Ifenprodil Represents a Novel First-in-Class Potential Treatment for Chronic Cough
Published: 2023-01-09 (Crawled : 21:00) - biospace.com/
AGNPF | $0.0708 178.69% 1.3K
|
Health Technology
|
| O: -4.07%
H: 0.0%
C: 0.0%
treatment pharmaceuticals potential study phase 2b
Algernon Pharmaceuticals Announces Plans for a 180 Patient Phase 2b Chronic Cough Study of Ifenprodil
Published: 2023-01-09 (Crawled : 12:20) - globenewswire.com
AGNPF | $0.0708 178.69% 1.3K
|
Health Technology
|
| O: -4.07%
H: 0.0%
C: 0.0%
pharmaceuticals study phase 2b
Streetwise Reports – Patients in Algernon’s Phase 2a Study Show Improved Lung Capacity
Published: 2022-07-20 (Crawled : 14:00) - algernonpharmaceuticals.com
AGNPF | $0.0708 178.69% 1.3K
|
Health Technology
|
| O: -2.62%
H: 3.0%
C: 2.89%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.62%
H: 0.0%
C: 0.0%
capacity study phase 2b
Algernon Pharmaceuticals Announces Positive Feedback from U.S. FDA for Phase 2b Ifenprodil Chronic Cough Study
Published: 2022-01-14 (Crawled : 15:00) - biospace.com/
AGNPF | $0.0708 178.69% 1.3K
|
Health Technology
|
| O: 9.2%
H: 0.0%
C: -4.78%
fda phase 2 als phase 2b positive chronic cough
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
Your saved searches
Save your searches and get alerts when important news are released.